Innovent Biologics Adds 10,000 Shares from Option Exercise; Issued Share Capital Reaches 1.74 Billion

Bulletin Express06-04 22:43

Innovent Biologics, Inc. (Innovent Biologics) filed its Monthly Return for the period ended 31 May 2026, reporting a marginal increase in issued share capital driven by employee option exercises.

Key Highlights

1. Share Capital Structure • Authorised share capital held steady at 5.00 billion ordinary shares with a par value of USD 0.00001 each, equivalent to USD 50,000. • Issued shares (excluding treasury shares) rose by 10,000 during May to 1,738.25 million. No treasury shares were held or cancelled, maintaining total issued shares at 1,738.25 million.

2. Drivers of Share Increase • The entire incremental issuance stemmed from the Pre-IPO Share Incentive Plan, where 10,000 options were exercised, reducing outstanding options under this plan to 8.59 million. • The exercise generated proceeds of HKD 23,165.94.

3. Share-Based Incentive Movements • Pre-IPO Share Incentive Plan: 10,000 options exercised; outstanding options now 8.59 million. • Post-IPO Share Option Scheme: 183,217 options cancelled; 44.09 million remain outstanding. • 2024 Share Scheme: 69,657 options lapsed; 5.49 million remain outstanding, with capacity for up to 129.35 million additional shares to be granted.

4. Capital Flexibility • No warrants, convertible securities, or other equity-linked instruments were issued or converted during the month. • Both 2018 and 2020 Restricted Share Plans remain terminated with no pending issuances.

5. Compliance • Innovent Biologics confirmed that it met the Hong Kong Stock Exchange’s minimum 25 % public-float requirement as of 31 May 2026. • All new share issuances complied with applicable listing rules and regulatory conditions.

Conclusion May 2026 saw limited equity dilution for Innovent Biologics, with only 10,000 new shares issued—representing a negligible 0.0006 % increase in share count—while authorised capital and treasury share positions remained unchanged. The company continues to maintain sufficient public float and retains substantial headroom for future equity-based incentives under its 2024 Share Scheme.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment